Lancet Series Article Calls for Changes to Approach to Fighting HIV-Associated TB
May 28, 2010
"The advent of ART [antiretroviral therapy] has been the most important event in tuberculosis control since the epidemic of HIV-associated tuberculosis began. However, the full potential of ART, in combination with HIV testing, tuberculosis screening, infection control, and isoniazid and co-trimoxazole preventive therapy, has yet to be realized," write the authors of a Lancet Series article that focuses on the situation in sub-Saharan Africa, "the epicenter of the HIV-associated tuberculosis epidemic." The piece features a "review of the interim international policy guidelines for collaborative tuberculosis and HIV activities," and an analysis of the logistics of delivery of HIV/AIDS treatment and TB prevention, among other things. The authors also make recommendations for the scaling up of HIV-TB prevention, testing and treatment (Harries et al., 5/29).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)